Human Anti-FAS Recombinant Antibody (clone E09) (CAT#: PABL-730)

Figure 1 Directed evolution of Fas antibody E09.

( a ) Analysis of the 44 highest affinity E09 variant antibodies from the six selection rounds, R1-R6. Surrogate affinity was determined using a six-point antigen titration in an ELISA-based assay. ( b ) Individual energy contribution of the seven mutations in the top clone EP6b_B01 to affinity improvement. Free energy of binding compared with the parent ( DD G 0 (mut-WT)) of single-point mutants and revertants in the EP6b_B01 sequence context are shown in white and grey, respectively. Theoretical additive values of the point mutant and the revertant are shown in dashed black. Energy calculations were based on BIAcore affinity measurement of scFvs for recombinant Fas. ( c ) Structural basis for affinity improvement in EP6b_B01. The lower panels show close-up views from the squares in the upper panel. The left part of each panel shows the zoom from the structure FasR:E09 complex, the right part the zoom from FasR:EP6b_B01. Hydrogen bonds are indicated as black dashed lines

Chodorge, M., Züger, S., Stirnimann, C., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. R. (2012). A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell death and differentiation, 19(7), 1187.

Figure 2 E09 variants with higher affinity are less potent agonists.

(a) Dose-dependent killing of Jurkat cells by E09 parent antibody, affinity optimised variants, or negative control CAT002. Dose response curves were plotted from cell-viability data following treatment with each of the antibodies. The cell-viability assay was performed in quadruplicate and error bars indicate the S.D. between replicates. The affinity of each antibody for Fas is also labelled next to the relevant curve. (b) The rate of koff (s1) for E09 and variant antibodies, as determined by SPR, was plotted against the Jurkat cell-killing efficiency. The parent antibody E09 is indicated by a circle containing a cross, the directed evolution variants are shown as unfilled circles and point mutants are shown as filled circles.

Chodorge, M., Züger, S., Stirnimann, C., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. R. (2012). A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell death and differentiation, 19(7), 1187.

Figure 3 Analysis of antibody E09 agonism of Fas by comparison to other agonists.

Jurkat cells were incubated for 8 h with the indicated IgGs or FasL at different concentrations. CAT002 was an unrelated IgG negative control. ( a ) The turnover of the effector caspase substrate z-DEVD-aminoluciferin was measured in relation to the concentration of each agonist or control antibody. ( b ) The amount of oligonucleosomes present in the cytosol, an indicator of DNA fragmentation during apoptosis, was detected by an antibody-based assay and plotted versus the concentration. All experiments were performed in triplicate and error bars indicate the standard deviation between replicates.

Chodorge, M., Züger, S., Stirnimann, C., Briand, C., Jermutus, L., Grütter, M. G., & Minter, R. R. (2012). A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell death and differentiation, 19(7), 1187.